resTORbio (resTORbio) NonCurrent Deferred Liabilities : $0.00 Mil (As of Jun. 2020)

View and export this data going back to 2018. Start your Free Trial

What is resTORbio NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

resTORbio's non-current deferred liabilities for the quarter that ended in Jun. 2020 was $0.00 Mil.

resTORbio NonCurrent Deferred Liabilities Historical Data

The historical data trend for resTORbio's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

resTORbio NonCurrent Deferred Liabilities Chart

resTORbio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

NonCurrent Deferred Liabilities

resTORbio Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial											-	-	-	-	-

resTORbio NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of resTORbio's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

resTORbio (resTORbio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » resTORbio Inc (NAS:TORC) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Boylston Street, 13th Floor, Boston, MA, USA, 02116

Website

https://www.restorbio.com

resTORbio Inc is a clinical-stage biopharmaceutical company. It mainly focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company focuses on the mechanistic target of rapamycin (mTOR) pathway which regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1. It is also involved in the development of RTB101 which is a small molecule, potent TORC1 inhibitor. The company's pipeline products include RTB101 and RTB101+ everolimus.